Other Vaccines - Indonesia

Indonesia

Highlights

In Indonesia, the revenue in the Other Vaccines market is estimated to reach US$147.10m by the year 2024.
It is anticipated that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 10.94%, ultimately leading to a market volume of US$247.20m by 2029.
In terms of global comparison, United States is projected to generate the highest revenue of US$24.73bn in 2024.
Indonesia is experiencing a growing demand for other vaccines due to increasing awareness of preventive healthcare.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in Indonesia has been experiencing significant growth in recent years.

Customer preferences: Indonesian customers are becoming increasingly aware of the importance of vaccination in preventing the spread of infectious diseases. This has led to a growing demand for a wider range of vaccines, including those for diseases other than the usual childhood vaccines.

Trends in the market: One of the main trends in the Other Vaccines market in Indonesia is the increasing popularity of travel vaccines. As more Indonesians travel abroad, they are becoming more aware of the need to protect themselves against diseases that may not be prevalent in Indonesia. This has led to a growing demand for vaccines such as yellow fever, typhoid, and hepatitis A and B.Another trend in the market is the growing demand for vaccines for adults. While childhood vaccines are well-established in Indonesia, there is a growing need for vaccines for adults, particularly for diseases such as influenza and pneumococcal disease.

Local special circumstances: One of the unique challenges facing the Other Vaccines market in Indonesia is the country's geography. Indonesia is an archipelago of over 17,000 islands, which can make it difficult to distribute vaccines to more remote areas. This has led to innovative solutions, such as using drones to deliver vaccines to more remote communities.

Underlying macroeconomic factors: The growth of the Other Vaccines market in Indonesia is being driven by a number of macroeconomic factors. One of the main drivers is the country's growing middle class, which is increasingly able to afford healthcare services, including vaccinations. Additionally, the Indonesian government has made significant investments in the healthcare sector in recent years, which has helped to improve access to vaccines for many Indonesians. Finally, the country's strong economic growth has helped to create a more favorable environment for businesses operating in the healthcare sector.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.